Healthcare Providers and Services
Company Overview of Biodesix, Inc.
Biodesix, Inc., a molecular diagnostic company, develops patient care improvement products for personalized medicine. It offers VeriStrat, a clinically validated serum test for advanced non-small cell lung cancer patients; and Clinical Laboratory Improvement Amendments (CLIA) Laboratory to test clinical samples in a CLIA-accredited setting. The company also offers ProTS, a set of analysis algorithms that enable the use of matrix-assisted, laser desorption ionization mass spectrometry for clinical diagnostics. In addition, it designs and implements biomarker development process. Biodesix, Inc. was founded in 2005 and is headquartered in Boulder, Colorado.
2970 Wilderness Place
Boulder, CO 80301
Founded in 2005
Key Executives for Biodesix, Inc.
Chief Executive Officer and Director
Vice President of Legal & Regulatory Affairs
Compensation as of Fiscal Year 2014.
Biodesix, Inc. Key Developments
Biodesix, Inc. Announces Executive Appointments
Feb 18 15
Biodesix, Inc. announced that Wendy Blosser is joining the company, and will serve as Vice President, Sales driving the sales of Biodesix expanding portfolio of blood-based tests in oncology. In addition, two other leaders have stepped into newly created roles: Jasmine Gruia-Gray, PhD. has assumed management of all marketing activities as the Vice President of Marketing and Robin Cowie has been promoted to the newly created role of Vice President, Reimbursement and Health Care Economics. Ms. Blosser is an oncology industry veteran who most recently held the position of US Vice President of Sales at Integrated Oncology. Ms. Cowie joined Biodesix in 2011 as the company's first director of reimbursement. Ms. Cowie's previous experience in reimbursement, payer and government affairs came during several years at Precision Therapeutics, Inc. Dr. Gruia-Gray joined Biodesix in 2014. Previously, she held the position of Vice President, Global Marketing at Affymetrix, Inc.
AVEO Oncology and Biodesix, Inc. Announces Presentation of Results from A Retrospective Exploratory Analysis Using Veristrat
Sep 29 14
AVEO Oncology and Biodesix, Inc. announced the presentation of results from a retrospective exploratory analysis using VeriStrat, a commercially available serum protein test, to identify patients most likely to benefit from the addition of ficlatuzumab, AVEO's HGF inhibitory antibody, to epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) therapy in a randomized Phase 2 study of ficlatuzumab and gefitinib (IRESSA) in previously untreated Asian subjects with non-small cell lung cancer (NSCLC). The results, presented in a poster session (abstract #8195) at the 2014 Congress of the European Society for Medical Oncology (ESMO), suggest that VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone. A total of 188 patients were enrolled in a randomized Phase 2 study (P6162) designed to compare the combination of ficlatuzumab and gefitinib with gefitinib alone in treatment-naïve Asian patients with non-small cell lung adenocarcinoma. For this retrospective exploratory analysis, 180 serum samples were assigned a VeriStrat label of either "Good" (VSG) or "Poor" (VSP) (VSG=145, VSP=35). While the study failed to demonstrate improved overall survival (OS) or progression-free survival (PFS) over gefitinib alone in the intent-to-treat population, the addition of ficlatuzumab to gefitinib provided significant clinical benefit to the VSP subgroup. No benefit was observed in the VSG subgroup in either OS (Median 24.7 mo for ficlatuzumab + gefitinib [n=69] vs not reached for gefitinib alone [n=76]; HR 1.18, p=0.492) or PFS (Median 5.6 mo for ficlatuzumab + gefitinib vs 5.6 mo for gefitinib alone; HR 1.06, p=0.753). Despite the small sample sizes, similar patterns in OS and PFS based on VeriStrat stratification were also observed in patients with known EGFR mutations (n=71) and VSP classification (n=11). Based on these data, in April 2014, AVEO and Biodesix(R) entered into a worldwide agreement to develop and commercialize ficlatuzumab with a Biodesix companion diagnostic test. As part of this agreement, AVEO and Biodesix plan to conduct a confirmatory Phase 2 study using a Biodesix VeriStrat "Poor" classification as a selective biomarker for the combination of ficlatuzumab and an EGFR-TKI, versus an EGFR TKI alone, in previously untreated, EGFR mutation-positive patients with advanced non-small-cell lung cancer. The study is expected to initiate before year-end.
Biodesix, Inc. Announces Board Appointments
Sep 25 14
Biodesix, Inc. announced two key additions to its leadership team. Richard Hockett, M.D., assumes the role of chief medical officer, overseeing the regulatory, medical and clinical strategy for Biodesix' expanding pipeline of new products. Jasmine Gruia-Gray, Ph.D., has been named vice president of strategic marketing, a role in which she will engage the marketplace on the clinical value of using noninvasive diagnostics to guide targeted therapy for patients. Dr. Hockett, a board certified clinical pathologist and champion of personalized medicine, brings three decades of experience in applying biomarkers to clinical medicine. He most recently served as chief medical officer for CombiMatrix and before that as chief medical officer for Affymetrix. Meanwhile, Dr. Gruia-Gray has joined Biodesix to lead marketing efforts for the company and its novel diagnostic products. Prior to joining Biodesix, Jasmine held marketing leadership roles at Affymetrix and Thermo Fisher Scientific (formerly Dionex Corp.) where she engaged scientific thought leaders to enhance the corporate brand and brought the 'voice of the customer' inside the company.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 31, 2014